NextCell Pharma AB

Stockholm Stock Exchange NXTCL.ST

NextCell Pharma AB EBITDA for the year ending August 31, 2024: USD -3.97 M

NextCell Pharma AB EBITDA is USD -3.97 M for the year ending August 31, 2024, a -10.99% change year over year. EBITDA means earnings before interest, taxes, depreciation, and amortization, which measures a company's operating performance by excluding non-operating expenses.

NextCell Pharma AB EBITDA for the year ending August 31, 2023 was USD -3.58 M, a -12.36% change year over year.
NextCell Pharma AB EBITDA for the year ending August 31, 2022 was USD -3.18 M, a -13.89% change year over year.
NextCell Pharma AB EBITDA for the year ending August 31, 2021 was USD -2.80 M, a -40.32% change year over year.
NextCell Pharma AB EBITDA for the year ending August 31, 2020 was USD -1.99 M, a -11.40% change year over year.

Key data

Date	EBITDA	Net Income	EPS (Diluted)	Shares (Diluted, Weighted)

Stockholm Stock Exchange: NXTCL.ST

NextCell Pharma AB

CEO	Dr. Mathias Svahn Ph.D.
IPO Date	July 13, 2017
Location	Sweden
Headquarters	Karolinska Institutet Science Park
Employees	17
Sector	Health Care
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

NextCell Pharma AB, a biopharmaceutical company, engages in the research and development of novel stem cell therapies in Sweden. The company develops ProTrans, a drug candidate comprising stem cells primarily for treating autoimmune and inflammatory diseases. It also provides Cellaviva, a stem cell bank for the family-saving of stem cells from umbilical cord blood and umbilical cord tissue. NextCell Pharma AB was incorporated in 2014 and is based in Huddinge, Sweden.

Key trends

Past 5 years